467 reports of this reaction
2.4% of all DEXAMETHASONE SODIUM PHOSPHATE reports
#4 most reported adverse reaction
ANAEMIA is the #4 most commonly reported adverse reaction for DEXAMETHASONE SODIUM PHOSPHATE, manufactured by Amneal Pharmaceuticals LLC. There are 467 FDA adverse event reports linking DEXAMETHASONE SODIUM PHOSPHATE to ANAEMIA. This represents approximately 2.4% of all 19,106 adverse event reports for this drug.
Patients taking DEXAMETHASONE SODIUM PHOSPHATE who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for DEXAMETHASONE SODIUM PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for DEXAMETHASONE SODIUM PHOSPHATE:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 467 FDA reports for DEXAMETHASONE SODIUM PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 2.4% of all adverse event reports for DEXAMETHASONE SODIUM PHOSPHATE, making it a notable side effect.
If you experience anaemia while taking DEXAMETHASONE SODIUM PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.